Advances in medical treatment of Cushing’s disease

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert Review of Endocrinology & Metabolism

• Publication date

  2007-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/17446651.2.6.735PMID 30290469
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Laparoscopic adrenalectomy].

  2009cited by this paper
• [Medical treatment for Cushing's syndrome].

  2008cited by this paper
• Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

  2007cited by this paper
• Mapping the contribution of β3-containing GABAA receptors to volatile and intravenous general anesthetic actions

  2007cited by this paper
• Cabergoline treatment in Cushings disease: effect on hypertension, glucose intolerance and dyslipidemia.

  2007cited by this paper
• Etomidate Use for Cushing's Syndrome Caused by an Ectopic Adrenocorticotropic Hormone–Producing Tumor

  2007cited by this paper
• Drugs and valvular heart disease.

  2007cited by this paper
• Ineffectiveness of rosiglitazone therapy in Nelson's syndrome.

  2007cited by this paper
• Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's diseaseGiraldi FP, Scaroni C, Arvat E, et al (Univ of Milan, Italy; Univ of Padua, Italy; Univ of Turin, Italy) Clin Endocrinol (Oxf) 64:219–224, 2006§

  2007cited by this paper
• Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease.

  2007cited by this paper
• Dopamine agonists and the risk of cardiac-valve regurgitation.

  2007cited by this paper
• Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome.

  2007cited by this paper
• [Use of cabergoline in persisting Cushing's disease].

  2006cited by this paper
• Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease

  2006cited by this paper
• Retinoic acid as a novel medical therapy for Cushing's disease in dogs.

  2006cited by this paper
• Effects of Chronic Administration of PPAR-γ Ligand Rosiglitazone in Cushing's Disease

  2006cited by this paper
• Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases.

  2006cited by this paper
• The PPAR‐gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome

  2006cited by this paper
• Identification of a GABAA Receptor Anesthetic Binding Site at Subunit Interfaces by Photolabeling with an Etomidate Analog

  2006cited by this paper
• New aspects in the diagnosis and treatment of Cushing disease.

  2006cited by this paper
• The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.

  2006cited by this paper
• α5GABAA Receptors Mediate the Amnestic But Not Sedative-Hypnotic Effects of the General Anesthetic Etomidate

  2006cited by this paper
• PPAR‐γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti‐proliferative effect of the glitazones is independent of the PPAR‐γ receptor

  2006cited by this paper
• Laparoscopic adrenalectomy.

  2006cited by this paper
• Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia

  2005cited by this paper
• Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

  2005cited by this paper
• Long‐term remission rates after pituitary surgery for Cushing's disease: the need for long‐term surveillance

  2005cited by this paper
• Cardiovascular Risk In Cushing's Syndrome

  2005cited by this paper
• Utilisation de la cabergoline dans la maladie de Cushing non contrôlée

  2005cited by this paper
• Pioglitazone treatment in Cushing’s disease

  2005cited by this paper
• Pharmacologic Management of Cushing Syndrome

  2005cited by this paper
• Novel Insights from Clinical Experience

  2005cited by this paper
• Cushing's Syndrome and Bone

  2005cited by this paper
• Pharmacologic management of Cushing syndrome : new targets for therapy.

  2005cited by this paper
• Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease.

  2005cited by this paper
• Potential indications for somatostatin analogs in Cushing's syndrome.

  2005cited by this paper
• The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

  2005cited by this paper
• Cognitive function and cerebral assessment in patients who have Cushing's syndrome.

  2005cited by this paper
• Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats.

  2005cited by this paper
• Cabergoline plus lanreotide for ectopic Cushing's syndrome.

  2005cited by this paper
• Effectiveness of long‐term rosiglitazone administration in patients with Cushing's disease

  2005cited by this paper
• Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission.

  2004cited by this paper
• Dopamine receptor expression and function in corticotroph pituitary tumors.

  2004cited by this paper
• Novel medical approaches for the treatment of Cushing’s disease

  2004cited by this paper
• Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease.

  2004cited by this paper
• Effects of acute and chronic ketoconazole administration on hypothalamo--pituitary--adrenal axis activity and brain corticotropin-releasing hormone.

  2004cited by this paper
• The Role of Somatostatin Analogs in Cushing's Disease

  2004cited by this paper
• Medical Therapy of Cushing's Disease

  2004cited by this paper
• Effect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenoma

  2004cited by this paper
• Nelson’s Syndrome: Complete Remission with Cabergoline but Not with Bromocriptine or Cyproheptadine Treatment

  2004cited by this paper
• Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-γ ligand, rosiglitazone, in Cushing’s disease

  2004cited by this paper
• Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results.

  2004cited by this paper
• Pharmacological characterisation of native somatostatin receptors in AtT‐20 mouse tumour corticotrophs

  2003cited by this paper
• Steroid Synthesis Inhibition with Ketoconazole and its Effect upon the Regulation of the Hypothalamus–Pituitary–Adrenal System in Healthy Humans*

  2003cited by this paper
• Diagnosis and complications of Cushing's syndrome: a consensus statement.

  2003cited by this paper
• Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.

  2002cited by this paper
• The Medical Management of Cushing's Syndrome

  2002cited by this paper
• Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas

  2002cited by this paper
• Metyrapone for Cushing's syndrome.

  2002cited by this paper
• Macroprolactinoma associated with Cushing’s disease, successfully treated with cabergoline

  2002cited by this paper
• SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.

  2002cited by this paper
• Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in nonectopic cushing’s syndrome

  2002cited by this paper
• Somatostatin Receptor Subtypes 2 and 5 Inhibit Corticotropin-Releasing Hormone-Stimulated Adrenocorticotropin Secretion from AtT-20 Cells

  2002cited by this paper
• Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome.

  2001cited by this paper
• Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).

  2001cited by this paper
• Retinoic acid prevents experimental Cushing syndrome.

  2001cited by this paper
• Effect of the Serotonin Antagonists Ritanserin and Ketanserin in Cushing's Disease

  2000cited by this paper
• Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline

  1999cited by this paper
• Medical therapy for Cushing's disease.

  1999cited by this paper
• Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis.

  1998cited by this paper
• Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism.

  1996cited by this paper
• Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group.

  1995cited by this paper
• Octreotide exerts different effects in vivo and in vitro in Cushing's disease.

  1994cited by this paper
• The medical treatment of Cushing's syndrome.

  1993cited by this paper
• Ketoconazole treatment in Cushing's syndrome: experience in 34 patients

  1991cited by this paper
• Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.

  1990cited by this paper
• Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in cushing's syndrome

  1988cited by this paper
• RESPONSE OF PITUITARY‐ADRENAL AXIS TO CORTICOTROPHIN RELEASING HORMONE IN PATIENTS WITH CUSHING'S DISEASE BEFORE AND AFTER KETOCONAZOLE TREATMENT

  1987cited by this paper
• PROLONGED REMISSION IN FLORID CUSHING'S SYNDROME FOLLOWING METYRAPONE TREATMENT

  1981cited by this paper
• Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases.

  1979cited by this paper
• Treatment of Cushing's disease with o,p'-DDD.

  1979cited by this paper
• Cyproheptadine-induced remission of Cushing's disease.

  1975cited by this paper

• Update on Hypercortisolism Therapy.

  2016cites this paper
• Pasireotide for the treatment of Cushing's disease

  2010cites this paper
• Corticotroph adenoma in the dog: pathogenesis and new therapeutic possibilities.

  2010cites this paper
• Pituitary-directed medical treatment of Cushing’s disease

  2009cites this paper